<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="UTF-8">
    <meta name="viewport" content="width=device-width, initial-scale=1.0">
    <title>24 Myeloma</title>
    <link href="https://fonts.googleapis.com/css2?family=Inter:wght@400;500;600;700&display=swap" rel="stylesheet">
    <link rel="stylesheet" href="../styles/main.css">
    <!-- Include MathJax -->
    <script>
    MathJax = {
        tex: {
            inlineMath: [['$', '$'], ['\\(', '\\)']],
            displayMath: [['$$', '$$'], ['\\[', '\\]']],
            processEscapes: true,
            processEnvironments: true,
            tags: 'ams' // Use AMS numbering of equations
        },
        svg: { fontCache: 'global' },
        options: {
            skipHtmlTags: ['script', 'noscript', 'style', 'textarea', 'pre']
        }
    };
    </script>
    <script src="https://polyfill.io/v3/polyfill.min.js?features=es6"></script>
    <script id="MathJax-script" async src="https://cdn.jsdelivr.net/npm/mathjax@3/es5/tex-mml-chtml.js"></script>
</head>
<body>
    <div class="container">
        <article class="document-section" role="main">
            <!-- Top Navigation -->
            <nav class="document-nav" role="navigation" aria-label="Document Sections">
                <div class="nav-links">
                    <a href="../index.html" class="nav-button">
                        <span class="nav-icon"></span>
                        <span class="nav-text">Table of Contents</span>
                    </a>
                    <a href="haematology-23-chronic-lymphocytic-leukaemia.html" class="nav-button">
                        <span class="nav-icon">←</span>
                        <span class="nav-text">Previous Section</span>
                    </a>
                    <div class="document-progress">
                         <div class="progress-bar" aria-hidden="true">
                            <div class="progress-fill" style="width: 60%;"></div>
                        </div>
                       <span class="progress-text">Lecture 24 of 40</span>
                    </div>
                    <a href="haematology-25-lymphoma-I-hodgkin-lymphoma.html" class="nav-button">
                        <span class="nav-text">Next Section</span>
                        <span class="nav-icon">→</span>
                    </a>
                </div>
            </nav>

            <header class="section-header">
                <h1 class="section-title">24 Myeloma</h1>
                <div class="title-underline"></div>
            </header>

            <main class="section-content">
                
                <section id="myeloma-intro" class="content-section" aria-labelledby="section-heading-1">
                    <div class="content-card">
                        <p>Multiple myeloma (MM) is a malignant disorder of plasma cells characterized by:</p>
                        <ol>
                            <li>a monoclonal paraprotein in serum and/or urine;</li>
                            <li>bone changes leading to pain and pathological features; and</li>
                            <li>excess plasma cells in the bone marrow.</li>
                        </ol>
                    </div>
                </section>

                <section id="incidence" class="content-section" aria-labelledby="section-heading-2">
                    <h2 id="section-heading-2" class="section-heading">
                        <span class="heading-text">Incidence</span>
                    </h2>
                    <div class="content-card">
                        <p>Approximately 50 cases/million population; 15% of lymphoid malignancies; 2% of all malignancies; twice as common in black than white people; slightly more common in males than females; median age at diagnosis 71 years.</p>
                    </div>
                </section>

                <section id="aetiology-pathogenesis" class="content-section" aria-labelledby="section-heading-3">
                    <h2 id="section-heading-3" class="section-heading">
                        <span class="heading-text">Aetiology and pathogenesis</span>
                    </h2>
                    <div class="content-card">
                        <p>The aetiology is unknown. The cell of origin is probably a postgerminal centre B-lymphoid cell. The cells all secrete the same immunoglobulin (Ig) or Ig component, e.g. part of a heavy chain attached to a light chain or light chain ($\kappa$ or $\lambda$) alone. Rarely (&lt;1%) the cells are non-secretory. Interleukin-6 (IL-6) from myeloma cells themselves or accessory cells promotes plasma cell growth. Tumour necrosis factor (TNF) and IL-1 mediate bone resorption. Oncogene mutations (e.g. ras, p53, myc) and translocations to 14q occur.</p>
                    </div>
                </section>

                <section id="clinical-features" class="content-section" aria-labelledby="section-heading-4">
                    <h2 id="section-heading-4" class="section-heading">
                        <span class="heading-text">Clinical features</span>
                    </h2>
                    <div class="content-card">
                        <ul>
                            <li>Skeletal involvement—bone pain, especially lower backache, or pathological fracture.</li>
                            <li>Marrow infiltration—features of bone marrow failure.</li>
                            <li>Infection—lack of normal immunoglobulins (immune paresis) and neutropenia.</li>
                            <li>Renal failure occurs in up to one-third of patients and is caused by hypercalcaemia, infection, deposition of paraprotein or light chains, uric acid or amyloid.</li>
                            <li>Amyloidosis may cause macroglossia, hepatosplenomegaly, cardiac or renal failure, carpal tunnel syndrome and autonomic neuropathy.</li>
                        </ul>
                    </div>
                </section>

                <section id="laboratory-features" class="content-section" aria-labelledby="section-heading-5">
                    <h2 id="section-heading-5" class="section-heading">
                        <span class="heading-text">Laboratory features</span>
                    </h2>
                    <div class="content-card">
                        <ul>
                            <li>Anaemia is frequent, often with neutropenia and thrombocytopenia. Erythrocyte sedimentation rate (ESR) often &gt;100 mm/h.</li>
                            <li>Blood film shows rouleaux with a bluish background staining, caused by the protein increase. Leuco-erythroblastic picture may be present.</li>
                            <li>Bone marrow shows &gt;10% plasma cells, often with multinucleate and other abnormal forms (Fig.24.1).</li>
                            <li>A paraprotein in serum and/or Bence Jones protein (light chains) in urine with suppression of normal serum immunoglobulins is usual (Fig. 24.2).</li>
                            <li>The paraprotein is IgG in 70%; IgA in 20%; IgM is uncommon; IgD and IgE are rare.</li>
                            <li>Serum $\beta_{2}$ microglobulin ($\beta_{2}\mathrm{M}$) often raised and higher levels correlate with worse prognosis.</li>
                            <li>Serum alkaline phosphatase usually normal.</li>
                            <li>X-rays, CT scan or MRI show lytic lesions typically in skull and axial skeleton and/or osteoporosis, often with pathological fractures (Fig.24.3). Occasional patients show localized plasma cell deposits, typically in the axial skeleton (multiple or solitary plasmacytoma).</li>
                            <li>Prognostic data include haemoglobin level, serum levels of $\beta_{2}\mathrm{M}$, serum creatinine and extent of skeletal disease.</li>
                        </ul>

                        <figure>
                            <img src="../assets/images/2025_09_09_3fc5c60a4aba104b7634g-065-1.jpg" alt="Fig. 24.1 Bone marrow aspirate showing infiltration by plasma cells, characteristic of multiple myeloma." class="content-image">
                            <figcaption>Fig. 24.1 Multiple myeloma: bone marrow showing infiltration by plasma cells.</figcaption>
                        </figure>

                        <figure>
                            <img src="../assets/images/2025_09_09_3fc5c60a4aba104b7634g-066-1.jpg" alt="Fig. 24.2a Protein electrophoresis gel. Lane 22 is a normal control. Lane 23 shows a distinct paraprotein band. The panel on the right identifies this as IgG lambda type." class="content-image">
                            <figcaption>(a) Multiple myeloma protein electrophoresis. Lane 22 shows a normal patient. Patient 23 has a paraprotein. The panel on the right shows that this paraprotein reacts with IgG (G) and $\lambda$ (L) antisera, and is therefore of IgG $\lambda$ type.</figcaption>
                        </figure>
                        
                        <div class="table-container" style="margin-top: 2rem;">
                             <table class="content-table">
                                <caption>(b) Data from lane 23 presented numerically.</caption>
                                 <thead>
                                     <tr>
                                         <th>Name</th>
                                         <th>%</th>
                                         <th>g/L</th>
                                         <th>Normal (g/L)</th>
                                     </tr>
                                 </thead>
                                 <tbody>
                                     <tr>
                                         <td>Albumin</td>
                                         <td>27.2</td>
                                         <td>24.8</td>
                                         <td>35-47</td>
                                     </tr>
                                     <tr>
                                         <td>Gammaglobulin</td>
                                         <td>2.1</td>
                                         <td>1.9</td>
                                         <td>25-33</td>
                                     </tr>
                                     <tr>
                                         <td>Paraprotein</td>
                                         <td>47.6</td>
                                         <td>43.4</td>
                                         <td></td>
                                     </tr>
                                 </tbody>
                             </table>
                        </div>

                        <figure>
                            <img src="../assets/images/2025_09_09_3fc5c60a4aba104b7634g-066-3.jpg" alt="Fig. 24.3 Skull X-ray from a patient with multiple myeloma, showing multiple 'punched-out' lytic lesions." class="content-image">
                            <figcaption>Fig. 24.3 Multiple myeloma: skull X-ray showing multiple lytic lesions.</figcaption>
                        </figure>
                    </div>
                </section>

                <section id="treatment" class="content-section" aria-labelledby="section-heading-6">
                    <h2 id="section-heading-6" class="section-heading">
                        <span class="heading-text">Treatment</span>
                    </h2>
                    <div class="content-card">
                        <ul>
                            <li>Symptomless patients who are stable with normal blood counts and renal function, no skeletal disease and low levels of paraprotein warrant observation rather than therapy.</li>
                            <li>Chemotherapy: induction is usually with melphalan and prednisolone or combination chemotherapy, e.g. Adriamycin, BCNU, cyclophosphamide and melphalan (ABCM) given intermittently every 4-6 weeks.</li>
                            <li>Most patients will reach a stable (plateau) phase (clinically well with near normal blood count, &lt;5% plasma cells in bone marrow, stable paraprotein level) after 4-6 cycles of treatment. This lasts 1-3 years. $\alpha$-Interferon may prolong duration of plateau phase.</li>
                            <li>Intensive therapy, e.g. slow infusions of vincristine, Adriamycin and dexamethasone (VAD), more often (&gt;50%) leads to complete disappearance of paraprotein and normalization of blood and marrow morphology (complete remission).</li>
                            <li>Younger patients (&lt;60 years) may benefit from induction with courses of VAD followed by high-dose chemotherapy, e.g. with high-dose melphalan, followed by autologous peripheral blood stem cell transplant (PBSCT).</li>
                            <li>Most patients relapse and median survival is 4-6 years from diagnosis. Relapsed cases may be retreated with initial therapy or with other combinations.</li>
                            <li>Radiotherapy is helpful in relieving pain from localized skeletal disease; hemi-body radiotherapy may help to control systemic disease.</li>
                            <li>Allogeneic SCT may be curative if applied to selected patients early in the course of the disease.</li>
                            <li>Supportive care includes hydration to prevent/treat renal failure, allopurinol to prevent hyperuricaemia, hydration, steroids and bisphosphonates for hypercalcaemia, antibiotics and blood components. Bisphosphonates (e.g. sodium clodronate) are useful in reducing skeletal complications and may improve survival. Surgery may be required for complications (e.g. pathological fracture, spinal cord compression). Plasma exchange is helpful in reducing the paraprotein level quickly.</li>
                        </ul>
                    </div>
                </section>

                <section id="related-disorders" class="content-section" aria-labelledby="section-heading-7">
                    <h2 id="section-heading-7" class="section-heading">
                        <span class="heading-text">Related disorders</span>
                    </h2>
                    <div class="content-card">
                        <p><strong>Benign monoclonal gammopathy</strong> (also termed monoclonal gammopathy of undetermined significance, MGUS) is an indolent disorder, more common than myeloma and characterized by a low (&lt;20 g/L) and stationary serum level of paraprotein, no reduction in normal immunoglobulins, absence of skeletal abnormalities and of Bence Jones protein and less than 10% plasma cells in the marrow. It may progress slowly to myeloma in approximately 10-30% of patients.</p>
                        <p><strong>Primary amyloidosis</strong> also shows less than 10% marrow plasma cells and no skeletal lesions but Bence Jones protein and low-level serum paraprotein may occur. Treatment as for myeloma may be beneficial.</p>
                        <p><strong>Solitary plasmacytoma</strong> may occur in bone or in soft tissues, a low level of serum paraprotein may occur and some cases later develop myeloma.</p>
                        <p><strong>Waldenström's macroglobulinaemia</strong> is a chronic lymphoproliferative disorder with a median age at diagnosis of 72 years, and is associated with an IgM paraprotein. Hyperviscosity is more common and may cause visual disturbance, central nervous system changes (confusion, impaired conscious level) and headache. Cells resembling plasma cells and lymphocytes are present in the marrow and often in the spleen and lymph nodes.</p>
                        <p><strong>Plasma cell leukaemia</strong> is an aggressive disorder in which large numbers of plasma cells circulate. The prognosis is poor.</p>
                    </div>
                </section>

            </main>

            <!-- Bottom Navigation -->
             <nav class="document-nav" role="navigation" aria-label="Document Sections">
                <div class="nav-links">
                    <a href="../index.html" class="nav-button">
                        <span class="nav-icon"></span>
                        <span class="nav-text">Table of Contents</span>
                    </a>
                    <a href="haematology-23-chronic-lymphocytic-leukaemia.html" class="nav-button">
                        <span class="nav-icon">←</span>
                        <span class="nav-text">Previous Section</span>
                    </a>
                    <div class="document-progress">
                         <div class="progress-bar" aria-hidden="true">
                            <div class="progress-fill" style="width: 60%;"></div>
                        </div>
                       <span class="progress-text">Lecture 24 of 40</span>
                    </div>
                    <a href="haematology-25-lymphoma-I-hodgkin-lymphoma.html" class="nav-button">
                        <span class="nav-text">Next Section</span>
                        <span class="nav-icon">→</span>
                    </a>
                </div>
            </nav>

        </article>
    </div>
    <script src="../js/navigation.js"></script>
</body>
</html>